Volume 133, Issue 26



June 27, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Light chain specificity of cystic lung light chain deposition disease. See the article by Camus et al.

CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX–knockout mice
Wang et al report successful long-term correction of factor IX levels in knockout mice, using CRISPR/Cas9-mediated gene correction.

Hydroa vacciniforme–like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites
Cohen and colleagues describe the dichotomous presentation of hydroa vacciniforme–like lymphoproliferative disorder as it presents in Asian patients and white patients.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Flinn et al report acceptable safety, durable responses, and high rates of minimal residual disease–negative remissions in a phase 1b study of the combination of venetoclax and obinutuzumab in both untreated and relapsed/refractory chronic lymphocytic leukemia.

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation
Baker and colleagues demonstrate the impact of the dose of total body irradiation on the risk of secondary malignancies after allogeneic stem cell transplantation.

Proteomic evidence of specific IGKV1-8 association with cystic lung light chain deposition disease
Light chain deposition disease (LCDD) is a rare disorder associated with accumulation of light chains in basement membranes. Camus et al demonstrate that a new form of LCDD presenting as a cystic lung disorder arises from an intrapulmonary B-cell clone that has a selective repertoire of immunoglobulin k variable region specificity.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.